PPARGC1A and COVID-19: Therapeutic targeting of PGC-1α through small molecules or physical exercise is of interest because of three main reasons: firstly, it integrates all the above mentioned factors that are affected in COVID-19; secondly, due to its multifaceted roles in anti-inflammatory and anti-oxidant pathways as well as in improving mitochondrial function, all of which are disrupted in COVID-19; thirdly, it shows promise in neuroprotection [232,233,234,235,236,237,238].